Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

SOLACI PERIPHERAL | Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection

Here is a new SOLACI PERIPHERAL Case!

In this opportunity, Dr. Daniel Zanuttini (Arg.) presents “Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection”. This is the 8th clinical case presented by SOLACI Peripheral. The purpose of this space is to encourage and further the exchange of experiences and opinions, to keep advancing our knowledge in interventional cardiology. 

Take part in the discussions and leave your comments! 


Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection


Author: Daniel Zanuttini (Argentina).

Contact: danielzanuttini10@gmail.com.

Institution: Instituto de Cardiología de Sanatorio Británico. Rosario. Argentina.


Discover other SOLACI Peripheral clinical cases

Medical record 

  • 57-year-old male Caucasian patient.
  • Religion: Jehovah’s Witness.
  • Background: high blood pressure and dyslipidemia, treated with losartan 100 mg + amlodipine 5 mg/day and rosuvastatin 20 mg/day.
  • On September 15th, 2018, he made a consultation for retrosternal pain, lancinating, with arterial hypertension 190/120 mmHg and peripheral pulses (slightly decreased in the left femoral and popliteal arteries).
  • Multislice tomography: ascending thoracic aorta with preserved caliber; at 2 cm from the sinotubular junction we observe a dissection entrance, with helical attitude and great dilatation in the aortic arch (5.5 cm), continuing in the descending thoracic aorta up to the iliac arteries. (Fig. 1 and 2).

Fig. 1 and 2. Multislice CT showing a type A (type I) dissection.

Type A aortic dissection is a life-threatening disorder requiring a fast and precise diagnosis. Without repair, 75% of patients die within two weeks, and 90% dies within three months. Reconstructive surgery, using an extracorporeal circulation device, is considered the first therapeutic option.

The patient refuses to receive transfusion of blood products from third parties.      

Therefore, a hybrid treatment is chosen.

First stage: a “Y” graft is prepared to reconstruct brain circulation, with latero-terminal anastomosis between the ascending aorta and the prosthesis. This prosthesis is anastomosed with the brachiocephalic trunk and the left common carotid artery, which are ligated at their origin. Subsequently, the beginning of the left subclavian artery is ligated and a bypass is performed with a 10-mm prosthesis from the extra-thoracic portion, and the Y graft anastomosed in the ascending aorta is debranching (Fig. 3). During surgery, cell saver was used for red blood cell recovery.

A Talent 40x224x40 (Medtronic) thoracic stent is implanted via the right femoral artery from the ascending thoracic aorta up to the beginning of the descending aorta, with occlusion of the proximal tear, without complications. Patient is discharged 10 days after the surgery.

Fig. 3: “Y” graft to reconstruct cerebral circulation.

Fig. 4: Angiography showing optimal prosthesis expansion, supra-aortic vessel patency, and no false lumen patency.

A control multislice CT at 60 days shows complete endoprosthesis expansion, decreased aneurysmal dilatation, moderate stenosis distal to the stent, distal type I endoleak, with false lumen patency. Clinical treatment continues.

mA Multislice CT performed in October 2020 shows significant stenosis of the true lumen with greater distal type I endoleak. Correction with a Talent stent is conducted.

Asymptomatic clinical course; a control multislice CT is performed in June 2021.


Discover other SOLACI Peripheral clinical cases

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

SOLACI to Participate in EuroPCR 2026 with a Scientific Session Focused on the Management of Complex Coronary Lesions

The Latin American Society of Interventional Cardiology will have a prominent participation at EuroPCR 2026 through an institutional scientific session bringing together renowned international...

Relive SOLACI’s participation in the V International Congress of Clinical and Interventional Cardiology in the Dominican Republic

The Latin American Society of Interventional Cardiology actively participated in the “V International Congress of Clinical and Interventional Cardiology”, organized by the Asociación Dominicana...

The Preliminary Scientific Program for SOLACI & SBHCI 2026 Is Now Available

The SOLACI & SBHCI 2026 Congress is already beginning to take shape with the official release of its Preliminary Scientific Program — a high-impact...

SOLACI granted its scientific endorsement to CITIC 2026

The Latin American Society of Interventional Cardiology (SOLACI) has granted its scientific endorsement to CITIC 2026, one of the region’s leading academic and technological...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...

EuroPCR 2026 | Restoring vascular physiology: 4-year results of the BIOADAPTOR-RCT

Despite advances in drug-eluting stents, device-related events continue to increase beyond the first year after angioplasty. In this context, the DynamX system emerged as...